NFKB1 and head and neck squamous cell carcinoma: While promising in tumors with NF-κB-driven inflammation (e.g., colorectal, liver, HNSCC, and TNBC), these inhibitors are limited by systemic toxicity, off-target effects, rapid degradation, and compensatory activation of alternative pathways (e.g., PI3K, STAT3).